Short-term and long-term FK506 treatment alters the vascular reactivity of renal and mesenteric vascular beds

Journal of Pharmacological Sciences

Volumn 102, Issue 4, 2006, Pages 359-367

  Soydan, Guray ^a   Tekes, Ender ^a   Tuncer, Meral ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Bosentan; Endothelin 1; Isolated perfused kidney and mesentery; Malondialdehyde; Tacrolimus (FK506)

Indexed keywords

BOSENTAN; ENDOTHELIN 1; MALONALDEHYDE; NITROPRUSSIDE SODIUM; NORADRENALIN; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG MECHANISM; HYPERTENSION; KIDNEY BLOOD VESSEL; LONG TERM CARE; MALE; MESENTERY BLOOD VESSEL; NONHUMAN; OXIDATIVE STRESS; RAT; SHORT COURSE THERAPY; SURVIVAL; SYSTOLIC BLOOD PRESSURE; TISSUE LEVEL; VASCULAR DISEASE;

EID: 33845620705     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0060733     Document Type: Article

References (27)

1. Jain AB, Kashyap R, Rakela J, Starzl TE, Fung JJ. Primary adult liver transplantation under tacrolimus: more than 90 months actual follow-up survival and adverse events. Liver Transpl Surg. 1999;5:144-150.
2. Taylor DO, Barr ML, Radovancevic B, Renlund DG, Mentzer RM Jr, Smart FW, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant. 1999;18:336-345.
3. De Lima JJ, Xue H, Coburn L, Andoh TF, McCarron DA, Bennett WM, et al. Effects of FK506 in rat and human resistance arteries. Kidney Int. 1999;55:1518-1527.
4. Takeda Y, Miyamori I, Furukawa K, Inaba S, Mabuchi H. Mechanisms of FK506-induced hypertension in the rat. Hypertension. 1999;33:130-136.
5. Goodall T, Kind CN, Hammond TG. FK506-induced endothelin release by cultured rat mesangial cells. J Cardiovasc Pharmacol. 1995;26:482-485.
6. Marsen TA, Weber F, Egink G, Suckau G, Baldamus CA. Differential transcriptional regulation of endothelin-1 by immunosuppressants FK506 and cyclosporin A. Fundam Clin Pharmacol. 2000;14:401-408.
7. Benigni A, Morigi M, Perico N, Zoja C, Amuchastegui CS, Piccinelli A, et al. The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. Transplantation. 1992;54: 775-780.
8. Nakahama H, Fukunaga M, Kakihara M, Horio M, Fujiwara Y, Fukuhara Y, et al. Comparative effects of cyclosporine A and FK-506 on endothelin secretion by a cultured renal cell line, LLC-PK1. J Cardiovasc Pharmacol. 1991;17:172-173.
9. Tekes E, Soydan G, Tuncer M. The role of endothelin in FK506-induced vascular reactivity changes in rat perfused kidney. Eur J Pharmacol. 2005;517:92-96.
10. Touyz RM. Oxidative stress and vascular damage in hypertension. Curr Hypertens Rep. 2000;2:98-105.
11. Kim YI, Kobayashi M, Egashira T, Kawano K, Morimoto A, Kai T, et al. Augmentation of hepatocyte proliferation by immunosuppressant pretherapy is associated with up-regulation of malondialdehyde production. Res Exp Med. 1993;193:337-345.
12. Cediel E, Sanz-Rosa D, Oubina MP, de las Heras N, Gonzalez Pacheco FR, Vegazo O, et al. Effect of AT1 receptor blockade on hepatic redox status in SHR: possible relevance for endothelial function? Am J Physiol Regul Integr Comp Physiol. 2003;285:674-681.
13. Alexander CS. A new simple method for indirect determination of blood pressure in the rat. Proc Soc Exp Biol Med. 1957;94:368-372.
14. Cadoff EM, Venkataramanan R, Krajack A, Jain AS, Fung JJ, Todo S, et al. Assay of FK 506 in plasma. Transplant Proc. 1990;22:50-51.
15. Mihara M, Uchiyama M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem. 1978;86:271-278.
16. Schaffer MR, Fuchs N, Proksch B, Bongartz M, Beiter T, Becker HD. Tacrolimus impairs wound healing: a possible role of decreased nitric oxide synthesis. Transplantation. 1998;65:813-818.
17. Iskit AB, Senel I, Sokmensuer C, Guc MO. Endothelin receptor antagonist bosentan improves survival in a murine caecal ligation and puncture model of septic shock. Eur J Pharmacol. 2004;506:83-88.
18. Chen JC, Ma P. Mechanism of FK506-induced renal hypoperfusion and its reversion in rats. Acta Pharmacol Sin. 2001;22:1034-1038.
19. Uchida J, Miura K, Yamanaka S, Kim S, Iwao H, Nakatani T, et al. Renal endothelin in FK506-induced nephrotoxicity in spontaneously hypertensive rats. Jpn J Pharmacol. 1998;76:39-49.
20. Pernow J, Boutier JF, Franco-Cereceda A, Lacroix JS, Matran R, Lundberg JM. Potent selective vasoconstrictor effects of endothelin in the pig kidney in vivo. Acta Physiol Scand. 1988;134:573-574.
21. Simonson MS, Dunn MJ. Renal actions of endothelin peptides. Curr Opin Nephrol Hypertens. 1993;2:51-60.
22. Wong-Dusting HK, La M, Rand MJ. Mechanisms of the effects of endothelin on responses to noradrenaline and sympathetic nerve stimulation. Clin Exp Pharmacol Physiol. 1990;17:269-273.
23. Amorena C, Castro A, Muller A, Villamil MF. Direct vascular effects in the rat of the vehicles used for the intravenous and oral administration of cyclosporin A. Clin Sci (Lond). 1990;79:149-154.
24. Yaris E, Tuncer M, Ilhan M. Actions of cyclosporin A preparation and Cremophor-EL in rabbit mesenteric artery and thoracic aorta in vitro. Clin Sci (Lond). 1992;83:179-182.
25. Gardiner SM, March JE, Kemp PA, Fallgren B, Bennett T. Regional haemodynamic effects of cyclosporine A, tacrolimus and sirolimus in conscious rats. Br J Pharmacol. 2004;141:634-643.
26. Callera GE, Touyz RM, Teixeira SA, Muscara MN, Carvalho MH, Fortes ZB, et al. ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension. Hypertension. 2003;42:811-817.
27. Olyaei AJ, de Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care. 2001;7:384-389.